Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Heather A ParsonsTimothy BlewettXiangying ChuSainetra SridharKatheryn SantosKan XiongVandana G AbramsonAshka PatelJu ChengAdam BrufskyJustin RhoadesJeremy ForceRuolin LiuTiffany A TrainaLisa A CareyMothaffar F RimawiKathy D MillerVered StearnsJennifer SpechtCarla FalksonHarold J BursteinAntonio C WolffEric P WinerNabihah TayobIan E KropG Mike MakrigiorgosTodd R GolubErica L MayerViktor A AdalsteinssonPublished in: medRxiv : the preprint server for health sciences (2023)
NAT for TNBC reduced ctDNA TFx by 285-fold in responders and 24-fold in non-responders. In 58% (22/38) of patients, ctDNA TFx dropped below the detection level of a commercially available test, emphasizing the need for sensitive tests. Additional studies will determine if ctDNA-guided approaches can improve outcomes.
Keyphrases
- circulating tumor
- neoadjuvant chemotherapy
- cell free
- circulating tumor cells
- end stage renal disease
- locally advanced
- chronic kidney disease
- ejection fraction
- newly diagnosed
- lymph node
- papillary thyroid
- sentinel lymph node
- peritoneal dialysis
- type diabetes
- young adults
- risk factors
- rectal cancer
- radiation therapy
- early stage
- insulin resistance
- lymph node metastasis